Our voluntary Board of Trustees meets five times per year, with executive staff present.
David Mayhew CBE is former Chairman of J.P. Morgan Cazenove and now Vice Chairman of J.P. Morgan’s global investment bank and former Chairman of Cazenove Capital Holdings Ltd.
Besides excellence in his field, David also brings a strong personal commitment to driving forward Alzheimer’s Research UK to support new breakthroughs in dementia research and ultimately treatments to defeat dementia.
David was appointed by the Prime Minister as the new Dementia Envoy for the UK in March 2016. The role will see him work with organisations and leaders across the globe to promote the global fight against dementia. He will also play an important role in supporting the delivery of the 2020 Challenge on Dementia – the UK Government’s vision for tackling the condition over the next five years.
David is also a member of the Wellcome Trust Investment Committee, a Trustee of The Game and Wildlife Conservation Trust, a Trustee of David Rattray Memorial Trust and Member of the Takeover Panel Appeal Board.
Mike Cooper started working in advertising in 1984 at Saatchi & Saatchi, he has also worked in television but has worked at Omnicom Group for the last 17 years. He became CEO of PHD Worldwide in 2007, responsible for growing the Omnicom owned network, which today has over 80 offices in 66 countries. Under Mike’s leadership, PHD was awarded AdWeek’s ‘Global Media Agency of the Year’ in 2012 and in 2013 was Campaign’s ‘Network of the Year’ runner-up as well as ‘Global Media Agency of the Year’ at the Cristal Awards in both 2013 and 2014.Today PHD is one of the world’s fastest growing and most awarded media agencies, with over 3,000 staff working for major global brands like Unilever, Hewlett Packard, GSK, Elizabeth Arden, Bayer, Canon, Porsche, Hyatt, and SAP.
Mike was appointed as Deputy Chairman in 2016.
James is Chair of the Centre for Brain Repair at the University of Cambridge and Director of Medical Studies at King’s College Cambridge. He researches into treatments for
spinal cord injury and brain damage, and works on the design of clinical trials for spinal injury treatments.
After beginning his career in the oil industry, Nick spent many years in the City of London where he was employed as an equity investment analyst specialising in valuing assets and companies in the oil and gas sector. He finished his career there as head of the European oil and gas equity research team at Morgan Stanley. Since the turn of the millennium he has been self-employed, working as a consultant both to the energy and to the investment industries, and as a financial trainer.
Dr Rupert Evenett is a social entrepreneur and has 30 years’ experience in investment markets and corporate finance. He has been a director in the UK civil service and is active in the voluntary sector, particularly in social investment and in charity strategy and governance, which he has combined with research in political philosophy on citizenship and social justice.
He was Chair of national volunteering charity The Conservation Volunteers (TCV), a director of The Social Investment Business, and is currently on the board of Goldsmiths, University of London and of the Old Royal Naval College, Greenwich.
Shirley is Chief Executive of the Royal Society for Public Health & Institute of Healthcare Management and is an experienced voluntary sector leader in both the UK and the USA and has also held non-executive positions in both countries in the public and voluntary sectors. She was Chief Executive of Dyslexia Action, the UK’s leading independent provider of services for individuals with dyslexia and other specific learning difficulties for over a decade. Prior to RSPH she was Interim Chief Executive of Alzheimer’s Research UK for six months and worked on the ‘Dementia Challenge’. She is Chair of the thinktank, British Future.
Shirley has a UK degree in Social Work and an MSc in Social Administration from Columbia University in New York.
Dr Fiona Marshall is a Founder and Chief Scientific Officer of Heptares Therapeutics, which uses protein structures to design drugs to treat diseases including Alzheimer’s disease, migraine and cancer. Fiona has a PhD in Neuroscience from Cambridge and 25 years’ experience in drug discovery gained at GSK and Millenium Pharmaceuticals. She is currently Chair of the MRC Developmental Pathway Funding Scheme Committee and an advisor to the Crick Institute. Fiona is a Fellow of the Academy of Medical Sciences, the British Pharmacological Society and the Society of Biology.
Christopher brings a wealth of expertise from the financial sector. Since 2012 he has been a Senior Advisor to Morgan Stanley and prior to that served in a number of capacities for the company, including Vice Chairman – Institutional Securities, Head of Global Capital Markets and a member of the Firm’s Management Committee. He joined Morgan Stanley in 2006 from CQS, a hedge fund group, where he served as Chairman. He previously spent 19 years at Credit Suisse in a wide range of senior investment banking and executive positions. Christopher is Chaiman of Starcount Pte. and Artorius Wealth Management Limited.
Christopher became a Trustee of Alzheimer’s Research UK in 2015.
Barry Townsley CBE brings not only a wealth of financial and investment experience to the Board, but also a strong background in charitable activities having worked for many years with a number of charities in the health, education and arts sector. He is a Founder Member and Principal Sponsor of Stockley Academy; Vice Chairman of the Serpentine Gallery; Patron of Trinity Hospice London; Vice President of Weizmann Institute UK; Director of the William J. Clinton Foundation Insamlingsstiftelse; Chairman, Hobart Capital Markets; Director of Caprice Holdings Limited; and Director of United UTB Partners Limited. He became a Trustee of Alzheimer’s Research UK in 2015.